1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort ADaniel V.T. Catenacci, Y-K. Kang, Byoung Yong Shim et al.|Annals of Oncology|2021Cited by 14